Symptomatic Neurogenic Orthostatic Hypotension (NOH)

Also known as: Symptomatic Neurogenic Orthostatic Hypotension

Drug	Drug Name	Drug Description
DB06262	Droxidopa	A medication used to treat symptomatic neurogenic orthostatic hypotension (nOH) caused by dopamine beta-hydroxylase deficiency, non-diabetic autonomic neuropathy and primary autonomic failure caused by conditions such as Parkinson's disease.

Drug	Drug Name	Target	Type
DB06262	Droxidopa	Phenylalanine-4-hydroxylase	target
DB06262	Droxidopa	Alpha-1A adrenergic receptor	target
DB06262	Droxidopa	Alpha-1B adrenergic receptor	target
DB06262	Droxidopa	Alpha-1D adrenergic receptor	target
DB06262	Droxidopa	Alpha-2A adrenergic receptor	target
DB06262	Droxidopa	Alpha-2B adrenergic receptor	target
DB06262	Droxidopa	Alpha-2C adrenergic receptor	target
DB06262	Droxidopa	Beta-1 adrenergic receptor	target
DB06262	Droxidopa	Beta-2 adrenergic receptor	target
DB06262	Droxidopa	Beta-3 adrenergic receptor	target
DB06262	Droxidopa	Aromatic-L-amino-acid decarboxylase	enzyme
DB06262	Droxidopa	Monocarboxylate transporter 10	transporter
DB06262	Droxidopa	Sodium-dependent noradrenaline transporter	transporter

Drug	Drug Name	Phase	Status	Count
DB06262	Droxidopa	1	Completed	1
DB06585	Fipamezole	2	Unknown Status	1
DB15348	Ampreloxetine	3	Completed	1
DB15348	Ampreloxetine	3	Recruiting	1
DB15348	Ampreloxetine	3	Terminated	2
DB06262	Droxidopa	3	Completed	2
DB06262	Droxidopa	3	Terminated	1
DB00742	Mannitol	3	Terminated	1
DB06262	Droxidopa	4	Completed	1